FLUVOXAMINE AND IMPOTENCE

29 May 1994

The antidepressant fluvoxamine (Duphar's Faverin) has been used with some success to treat erectile dysfunction in men, according to the Journal of Sexual Health (April/May). If the potential of the drug is borne out in further study, it could become the first oral treatment for impotence and do away with the need for intrapenile injections in certain patient groups.

72 men whose impotence did not respond to psychosexual counselling were treated with either fluvoxamine (n=44) or placebo (n=28). Those in the fluvoxamine group received 100mg at bedtime for 24 weeks, while the others took placebo in the form of 200mg ascorbic acid at bedtime for 12 weeks.

"After six weeks of treatment with fluvoxamine, 18% of the patients were able to achieve a full erection, increasing to 30% at 12 weeks and 34% at 24 weeks, while only 7% (2 patients) achieved a similar response in the placebo group," said Dr K Mohanty, consultant in genito-urinary medicine at St Luke's Hospital in Bradford, UK.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight